Ruth Geraldes

Sep 3, 2024 | nature.com | Ruth Geraldes |Georgina Arrambide |Alex Rovira |Hans Lassmann |Patrick Waters |Declan T. Chard | +6 more

AbstractMyelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an immune-mediated demyelinating disease that is challenging to differentiate from multiple sclerosis (MS), as the clinical phenotypes overlap, and people with MOGAD can fulfil the current MRI-based diagnostic criteria for MS. In addition, the MOG antibody assays that are an essential component of MOGAD diagnosis are not standardized.